Myovant Sciences Ltd. (MYOV) financial statements (2021 and earlier)

Company profile

Business Address SUITE 1, 3RD FLOOR
LONDON, SW1Y 4LB
State of Incorp. CA
Fiscal Year End March 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
TTM
3/31/2019
3/31/2018
3/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments99156109181
Cash and cash equivalents83156109181
Short-term investments16   
Restricted cash and investments 1  
Receivables 110
Other undisclosed current assets12953
Total current assets:111167115184
Noncurrent Assets
Operating lease, right-of-use asset11
Property, plant and equipment2211
Other noncurrent assets543 
Other undisclosed noncurrent assets   0
Total noncurrent assets:19641
TOTAL ASSETS:130173119185
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:52113515
Accounts payable7 53
Accrued liabilities45543012
Interest and dividends payable 10 
Other undisclosed accounts payable and accrued liabilities (44)  
Debt16  
Due to related parties 023
Other undisclosed current liabilities055  
Total current liabilities:53723718
Noncurrent Liabilities
Long-term debt and lease obligation1193  
Long-term debt, excluding current maturities 93  
Operating lease, liability11
Liabilities, other than long-term debt 100
Deferred revenue and credits00
Deferred rent credit 1
Derivative instruments and hedges, liabilities   0
Other undisclosed noncurrent liabilities114244 
Total noncurrent liabilities:12597440
Total liabilities:1781698119
Stockholders' equity
Stockholders' equity attributable to parent(49)438167
Common stock0000
Common stock, share subscribed but unissued, subscriptions receivable   (0)
Additional paid in capital678506266252
Accumulated other comprehensive income (loss)(1)100
Accumulated deficit(726)(502)(228)(85)
Total stockholders' equity:(49)438167
TOTAL LIABILITIES AND EQUITY:130173119185

Income statement (P&L) ($ in millions)

12/31/2019
TTM
3/31/2019
3/31/2018
3/31/2017
Operating expenses(282)(265)(141)(56)
Other undisclosed operating loss(16)(8)(2)(28)
Operating loss:(298)(273)(143)(84)
Nonoperating income (expense)
(Foreign Currency Transaction Gain (Loss), before Tax)
  (0)0
Interest and debt expense(16)(9)(2) 
Loss from continuing operations before equity method investments, income taxes:(315)(282)(145)(83)
Other undisclosed income (loss) from continuing operations before income taxes992(0)
Loss from continuing operations before income taxes:(306)(273)(143)(84)
Income tax expense (benefit)(1)(0)(0)0
Net loss:(307)(274)(143)(83)
Other undisclosed net income attributable to parent8   
Net loss available to common stockholders, diluted:(299)(274)(143)(83)

Comprehensive Income ($ in millions)

12/31/2019
TTM
3/31/2019
3/31/2018
3/31/2017
Net loss:(307)(274)(143)(83)
Other comprehensive loss(1)   
Comprehensive loss:(308)(274)(143)(83)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent80(0)0
Comprehensive loss, net of tax, attributable to parent:(300)(273)(143)(83)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: